BackBayer AG Overview

Bayer AG EBIT

Track Bayer AG's EBIT ($5.7B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$28.00M
↑ 92.98% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$5.72B
↑ 204.03% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Bayer AG (BAYN.SW) FAQ

The latest EBIT for BAYN.SW is $5.7B as of September 2026. That compares with $1.9B in the prior-year period — up 204.0% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Bayer AG's historical trend and sector peers before judging valuation or financial health.

Over the past year, BAYN.SW's EBIT moved from $1.9B to $5.7B — a 204.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bayer AG's operating scale or balance-sheet position.

Against Healthcare companies, BAYN.SW currently prints $5.7B for EBIT, while the sector average sits near $1.9T. That is roughly 99.7% below the sector mean. Large gaps often invite a closer look at Bayer AG's growth, margins, and balance sheet.

A EBIT figure of $5.7B for BAYN.SW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting BAYN.SW's EBIT ($5.7B), review year-over-year change from $1.9B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers